Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

• Status: Completed
• Trial end date: 2009-09-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Acetaminophen

Criteria

Inclusion Criteria:

• Stable coronary artery disease for 3 months or more

• 18 years of age or older with a history of migraine with or without aura

• Must use acceptable contraception throughout the study

Exclusion Criteria:

• Pregnant, breast-feeding, or planning to become pregnant during this study

• 50 years of age or older when migraines began

• Other pain syndromes that might interfere with study assessments, uncontrolled psychiatric conditions, dementia, or significant neurological disorders (other than migraine)

• History of gastric, or small intestinal surgery, or has a disease that causes malabsorption